Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2014; 04(01): 17-19
DOI: 10.4103/2231-0770.127417
CASE REPORT

Isolation of Mycobacterium branderi, an unusual species from an acute myelogenous leukemia patient

Majid Marjani
Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
,
Maham Farshidpour
Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
,
Payam Tabarsi
Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
,
Fatemeh-Maryam Sheikholslami
Mycobacteriology Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
,
Parissa Farnia
Mycobacteriology Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

We report a case of pulmonary infection caused by Mycobacterium branderi, a slow growing non-tuberculosis mycobacteria, in a patient with acute myelogenous leukemia. The pulmonary disease was treated successfully with the combination of Ciprofloxacin, Doxycycline and Clarithromycin. M. branderi may be considered as an opportunistic pathogen, especially among immunologically compromised patients.

Keywords

Acute myelogenous leukemia - Mycobacterium branderi - PCR-restriction fragment length polymorphism


Publication History

Article published online:
09 August 2021

© 2014. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: National trends over three decades. Am J Respir Crit Care Med 2007;176:306-13.
  • 2 Tanaka E, Kimoto T, Matsumoto H, Tsuyuguchi K, Suzuki K, Nagai S, et al. Familial pulmonary Mycobacterium avium complex disease. Am J Respir Crit Care Med 2000;161:1643-7.
  • 3 McCallum AD, Watkin SW, Faccenda JF. Non-tuberculous mycobacterial infections in the Scottish Borders: Identification, management and treatment outcomes: A retrospective review. J R Coll Physicians Edinb 2011;41:294-303.
  • 4 Atif M, Sulaiman SA, Shafie AA, Ali I, Hassali MA, Saleem F. WHO guidelines for treatment of tuberculosis: The missing links. Int J Clin Pharm 2012;34:506-9.
  • 5 Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood 2012;120:3187-205.
  • 6 Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 1993;31:175-8.
  • 7 Identification of mycobacteria. Available from: http://www.app.chuv.ch/prasite/index.html. [Last updated on 2007 Sep 15; Last accessed on 2013 Oct 27].
  • 8 Brunello F, Ligozzi M, Cristelli E, Bonora S, Tortoli E, Fontana R. Identification of 54 mycobacterial species by PCR-restriction fragment length polymorphism analysis of the hsp65 gene. J Clin Microbiol 2001;39:2799-806.
  • 9 Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002;23:553-67.
  • 10 Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997;156:S1-25.
  • 11 Al Jarad N, Demertzis P, Jones DJ, Barnes NC, Rudd RM, Gaya H, et al. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis. Thorax1996;51:137-9.
  • 12 Brander E, Jantzen E, Huttunen R, Julkunen A, Katila ML. Characterization of a distinct group of slowly growing mycobacteria by biochemical tests and lipid analyses. J Clin Microbiol 1992;30:1972-5.
  • 13 Koukila-Kähkölä P, Springer B, Böttger EC, Paulin L, Jantzen E, Katila ML. Mycobacterium branderi sp. nov., a new potential human pathogen. Int J Syst Bacteriol 1995;45:549-53.
  • 14 Sugawara I, Kazumi Y, Otomo K, Ooki K, Mitarai S, Mori K. Mycobacterium branderi isolated from pus of a right pulmonary cavitary lesion. Jpn J Infect Dis 2005;58:187-8.
  • 15 Wolfe J, Turenne C, Alfa M, Harding G, Thibert L, Kabani A. Mycobacterium branderi from both a hand infection and a case of pulmonary disease. J Clin Microbiol 2000;38:3896-9.